IVEV

Inventiva S.A

IVEVF.US inventivapharma.com
Healthcare · Biotechnology
3.59
+0.00 (+0.00%)
USD · PINK
52-week range
2.28
5.75
Trading at 38% of the 52-week range
Market Cap
848.03M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-0.17
Div. Yield
N/A
% Institutions
49.93%
% Insiders
12.67%

1 Year

+57.5%

3 Year

-3.8%

10 Year

+49.6%
Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Company Information

▼
Company Name
Inventiva S.A
Sector
Healthcare
Industry
Biotechnology
Exchange
PINK
CIK: 0001756594
Currency: USD
Full Time Employees: 69
Phone: 33 3 80 44 75 00
Website: inventivapharma.com
Fiscal Year End: December
Description:

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Address:

50 rue de Dijon, Daix, France, 21121

People

▼

Directors & Officers

Name Title Year Born
Mr. Andrew Obenshain Chief Executive Officer 1974
Dr. Pierre Broqua Ph.D. Co-Founder 1962
Mr. Jean Volatier Executive VP Finance & Corporate Social Responsibility 1965
Dr. Martine Zimmermann Pharm.D. Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs 1969
Mr. Jason A. Campagna M.D., Ph.D. President of Research & Development and Chief Medical Officer 1966
Mr. Axel-Sven Malkomes Chief Financial Officer 1967
Mr. Christopher Benecchi Chief Operating Officer 1972
Ms. Susan Coles Chief Legal Officer 1966
Ms. Pamela Herbster Chief People Officer NA
Ms. Pascaline Clerc Ph.D. Executive Vice President of External and Corporate Affairs 1980

Financial Highlights

▼
Market Cap: $848.03M
EBITDA: $-132.50M
Book Value: $-0.17
Earnings/Share: $-2.21
Profit Margin: 0.00%
Operating Margin: -6,710.69%
ROA (TTM): -45.08%
ROE (TTM): -1,642.76%
Revenue (TTM): $6.76M
Revenue/Share (TTM): $0.04
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -89.90%

Valuation Metrics

Enterprise Value: $733.93M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 236.22M
Shares Float: 157.92M
% Insiders: 12.67%
% Institutions: 49.93%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

▼

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$4.48M
Cost of Goods Sold
adjust
$-2.91M
Gross Profit
subtotal
$1.57M
SG&A
adjust
$-49.05M
R&D
adjust
$-87.01M
Other Operating Expense
adjust
$-1.30M
Operating Income
subtotal
$-132.88M
Other / Non-Operating Items
adjust
$-221.12M
Net Income
subtotal
$-354.01M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IVEVF.US!